文献速递甲状腺疾病性腺与生殖内分泌

甲状腺疾病与女性不孕

Thyroid disorders and female infertility.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述甲状腺功能障碍(尤其是亚临床和临床甲状腺功能减退)及甲状腺自身免疫对女性生育力和辅助生殖技术结局的影响。尽管左甲状腺素广泛用于TSH阈值2.5 mIU/L的亚临床甲减治疗,但近期数据提示该阈值可能不改善生育结局,治疗决策应基于个体化评估。

要点

  • 甲状腺功能障碍和甲状腺自身免疫在育龄女性中常见,可能通过激素和免疫机制损害生育力。
  • 亚临床甲减和甲状腺功能正常的甲状腺自身免疫对生育的影响仍有争议,左甲状腺素治疗获益证据有限。
  • 辅助生殖技术中甲状腺状态和自身免疫可能影响卵巢反应、胚胎质量和妊娠结局,治疗应个体化。

核心结论

  • 甲状腺功能障碍和甲状腺自身免疫可能损害女性生育力,但亚临床甲减和甲状腺功能正常的甲状腺自身免疫的作用仍有争议。
  • 左甲状腺素在TSH阈值2.5 mIU/L时广泛使用,但近期数据提示该阈值可能不改善生育结局,治疗决策应个体化。

研究设计与样本

  • 本文为综述,综合当前证据和机制,探讨甲状腺功能障碍和甲状腺自身免疫对女性生育力及辅助生殖技术结局的影响。

主要发现

  • 临床甲状腺功能障碍明确影响生殖生理,但亚临床甲减和甲状腺功能正常的甲状腺自身免疫的作用仍有争议。
  • 尽管支持证据有限,左甲状腺素在临床实践中广泛使用,常以TSH阈值2.5 mIU/L定义亚临床甲减并开始治疗。
  • 近期数据提示实施该阈值可能不改善生育结局,且有采用更高TSH切点进行孕前诊断和治疗的倾向。
  • 辅助生殖技术中甲状腺状态和自身免疫可能影响卵巢反应、胚胎质量和妊娠结局。

关键数值与推荐

  • 左甲状腺素常以TSH阈值2.5 mIU/L定义亚临床甲减并开始治疗,但近期数据提示该阈值可能不改善生育结局。
  • 有采用更高TSH切点进行孕前诊断和治疗的倾向。

临床怎么用

  • 治疗决策应基于甲状腺功能、抗体状态和生殖背景的个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thyroid disorders, including both thyroid dysfunction and thyroid autoimmunity (TAI), are prevalent in women of reproductive age and may impair fertility through hormonal and immune-mediated mechanisms. This review synthesizes current evidence and underlying mechanisms regarding the impact of thyroid dysfunction, particularly subclinical and overt hypothyroidism, and TAI on female fertility and outcomes of assisted reproductive technology (ART). While overt thyroid dysfunction clearly affects reproductive physiology, the role of subclinical hypothyroidism (SCH) and euthyroid TAI remains controversial. Despite limited supporting evidence, levothyroxine (LT4) is widely used in clinical practice, often initiated at thyroid-stimulating hormone (TSH) thresholds of 2.5 mIU/L to define SCH and commence treatment. However, recent data suggest that implementing such thresholds may not be associated with improved fertility outcomes, and there is a growing tendency to adopt higher TSH cutoffs for diagnosis and treatment in the preconception setting. ART introduces additional considerations, with thyroid status and autoimmunity potentially influencing ovarian response, embryo quality, and pregnancy outcomes. In light of these uncertainties, treatment decisions increasingly rely on individualized assessment of thyroid function, antibody status, and reproductive context.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Unuane D, Velkeniers B, Poppe KG, et al. Thyroid disorders and female infertility. J Clin Endocrinol Metab. 2026. PMID: 41631700. doi:10.1210/clinem/dgag039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。